Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 3/20 | 0.50 |
| ▸ | PLAT | P00750 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | GRK6 | P43250 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505403 | 0.89 | NR1H2 (0.59) | NR1H2NR1H3ADORA2AADORA1DGAT1 | |
| SCHEMBL17279771 | 0.89 | NR1H2 (0.53) | NR1H2NR1H3ADORA2AADORA1PLAU | |
| SCHEMBL17279684 | 0.86 | NR1H2 (0.67) | NR1H2NR1H3ADORA2AADORA1DGAT1 | |
| SCHEMBL26094713 | 0.82 | NR1H2 (0.54) | NR1H2NR1H3ADORA2AADORA1MAPT | |
| SCHEMBL17279765 | 0.81 | NR1H2 (0.54) | NR1H2NR1H3ADORA2ADGAT1MAPT | |
| SCHEMBL17280065 | 0.81 | NR1H2 (0.57) | NR1H2NR1H3ADORA2AADORA1MAPT | |
| SCHEMBL18965904 | 0.81 | NR1H2 (0.53) | NR1H2NR1H3ADORA2AADORA1MAPT | |
| SCHEMBL7825137 | 0.80 | PLAU (0.66) | PLAUPLATPLGSMN1; SMN2LMNA | |
| SCHEMBL26465286 | 0.80 | ATAD2 (0.63) | NR1H2NR1H3ADORA2AADORA1DGAT1 | |
| SCHEMBL5201903 | 0.79 | NR1H2 (0.63) | NR1H2NR1H3ADORA2AADORA1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3067053-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1815206-B1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2939674-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2311455-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301536-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301538-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1815206-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044456-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | NR1H2 3235/4885NR1H3 3307/4885ADORA2A 1850/4885 |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | NSUN2, UPF1, NSUN3 | NR1H2 3235/4885NR1H3 3307/4885ADORA2A 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.